CAJ | 학술논문

目的：观察乳腺癌新辅助化疗前后雌激素受体（ER）、孕激素受体（PR）、人v-erb-B-2相关基因（c-erb-B-2）、P53基因（P53）、Ki67抗原（Ki67）表达的改变及意义以及与化疗疗效的关系。方法收集35例乳腺癌患者，新辅助化疗（NAC）采用紫杉类联合蒽环类方案4～6疗程后进行临床疗效评价；对比化疗前后ER、PR、c-erb-B-2、P53、Ki67变化以及与化疗疗效的关系。结果临床总有效率为91．42％，临床获益率（cCR＋cPR＋SD）为100．00％。NAC前后Ki67状态有12例发生变化，差异有统计学意义（P＜0．05）。Ki67数值有31例发生变化，Ki67数值在有效组、无效组分别有27例、1例降低，差异有统计学意义（P＜0．05）。结论NAC对ER、PR、c-erb-B-2、P53的状态无显著影响，而显著降低Ki67表达，Ki67可预测乳腺癌新辅助化疗的疗效。
목적：관찰유선암신보조화료전후자격소수체（ER）、잉격소수체（PR）、인v-erb-B-2상관기인（c-erb-B-2）、P53기인（P53）、Ki67항원（Ki67）표체적개변급의의이급여화료료효적관계。방법수집35례유선암환자，신보조화료（NAC）채용자삼류연합은배류방안4～6료정후진행림상료효평개；대비화료전후ER、PR、c-erb-B-2、P53、Ki67변화이급여화료료효적관계。결과림상총유효솔위91．42％，림상획익솔（cCR＋cPR＋SD）위100．00％。NAC전후Ki67상태유12례발생변화，차이유통계학의의（P＜0．05）。Ki67수치유31례발생변화，Ki67수치재유효조、무효조분별유27례、1례강저，차이유통계학의의（P＜0．05）。결론NAC대ER、PR、c-erb-B-2、P53적상태무현저영향，이현저강저Ki67표체，Ki67가예측유선암신보조화료적료효。
Objective To observe the immunohistochemical changes and significance of breast cancer after neoadjuvant chemothera-py,and to explore the relationship between ER,PR,c-erb-B-2,P53,Ki67 expression and chemotherapeutic effect.Methods Thirty-five cases of breast cancer patients were treated by neoadjuvant chemotherapy,which was taxanes and anthracyclines scheme for 4~6 cycles.Clinical e-valuation of the effect of neoadjuvant chemotherapy was done after the treatment.The relationship between ER,PR,c-erb-B-2,P53,Ki67 chan-ges and immuno-histochemical results with chemotherapeutic effect was contrasted before and after chemotherapy.Results The total effective rate was 91 .42%,and the clinical benefit rate was 1 00.00% (cCR+cPR+SD).After neoadjuvant chemotherapy,Ki67 changed in 31 pa-tients,which was statistically significant(P<0.05).The value of Ki67 in the effective group and invalid group was decreased in 27 cases and 1 case,respectively,and the difference was statistically significant(P<0.05).Conclusion Neoadjuvant chemotherapy has no significant in-fluence on ER,PR,c-erb-B-2,P53,but it can significantly decrease Ki67 expression.Ki67 can predict the effect of neoadjuvant chemotherapy for breast cancer.